Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

191
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
191
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

171
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
171
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

229
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
229
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

225
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
225
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

242
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
242
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

401
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
401

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Ten Years of Hydroxyurea for Ugandan Children with Sickle Cell Anemia.

The New England journal of medicine·2026
Same author

Persistent Splenomegaly Is Associated with Morbidity in Tanzanian Children with Sickle Cell Anemia: Secondary Analysis of the SPHERE Trial.

Acta haematologica·2026
Same author

Growth and puberty in African children with sickle cell anemia treated with hydroxyurea.

Blood advances·2026
Same author

Creative and Adaptive Solutions for Early Diagnosis of Sickle Cell Disease in Sub-Saharan Africa.

American journal of hematology·2026
Same author

Advancing Sickle Cell Disease Treatment in Sub-Saharan Africa: Challenges and Opportunities for Disease Modifying Therapies.

American journal of hematology·2026
Same author

Sickle Cell Disease in Sub-Saharan Africa: Progress and Potential.

American journal of hematology·2026
Same journal

Neurocognitive functioning of patients with sickle cell disease in low- and middle-income countries.

Blood global hematology·2026
Same journal

Hodgkin lymphoma treatment patterns and outcome disparities in low- and middle-income countries.

Blood global hematology·2026
Same journal

Immunogenomic profiles of HIV-associated classic Hodgkin lymphoma from Malawi.

Blood global hematology·2026
Same journal

Clinical integration of red cell genotyping in children with β-thalassemia major: a prospective observational study.

Blood global hematology·2026
Same journal

Urinary carbonic anhydrase 1 excretion is a marker of hemolysis-triggering conditions suitable for point-of-care testing.

Blood global hematology·2026
Same journal

Asian-type DEL among D-negative patients and donors in Malaysia can ease the demand for D-negative red cells and RhIG.

Blood global hematology·2026
查看所有相关文章

相关实验视频

Updated: Jan 8, 2026

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.9K

基尿素可降低患有状细胞贫血的儿童中风风险:系统性审查和元分析.

Emmanuela E Ambrose1, Paul Alikado Sabuni2, Don P Jason Iii3

  • 1Department of Pediatrics and Child Health, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.

Blood global hematology
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

氨酸有效降低患有状细胞贫血 (SCA) 的儿童中风风险,通过降低异常血流速度. 这种治疗是一种可行的输血替代方案,特别是在资源有限的地区.

更多相关视频

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.2K
Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

16.5K

相关实验视频

Last Updated: Jan 8, 2026

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.9K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.2K
Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

16.5K

科学领域:

  • 儿科血液学 儿科血液学
  • 神经学 神经学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 细胞贫血 (SCA) 是一种导致儿童中风的遗传性疾病.
  • 体多普勒 (TCD) 超声波评估SCA患者中风风险.
  • 目前的中风预防包括输血,在资源有限的环境中存在局限性.

研究的目的:

  • 系统地审查氧尿素在降低SCA儿童TCD速度和中风风险方面的有效性.
  • 为了澄清酸对TCD速度的影响的影响的大小和持续时间.

主要方法:

  • 在五个主要医疗数据库中对潜在的临床试验进行了系统审查.
  • 包括注册患有SCA的儿童的试验,使用TCD查,并在氧尿素治疗期间收集串行TCD速度和中风发病率数据.
  • 分析了涉及592名参与者的13项试验的数据.

主要成果:

  • 在0.5至2.6岁期间,基尿素显著降低了TCD平均速度-30cm/s,在大多数儿童中正常化.
  • 脑卒中发病率很低 (0.52-1.92每100个患者年),仅发生在持续高TCD值 (>200厘米/秒) 的患者中.
  • 基尿素在降低TCD速度和相关中风风险方面表现出有效性.

结论:

  • 基尿素是通过降低TCD速度来减轻儿科SCA中风风险的有效策略.
  • 它为输血提供了一种可行的替代方案,在资源有限的医疗机构中尤其有益.
  • 进一步的研究是有必要的,以优化剂量,评估长期的安全性,并评估在不同的人群中全面的好处.